MannKind Corporation has announced a definitive merger agreement to acquire scPharmaceuticals for up to $360 million in cash, marking the company's strategic expansion into cardiorenal medicine. The acquisition centers on FUROSCIX, an FDA-approved on-body infuser delivering furosemide for treating fluid overload in adult patients with chronic heart failure and chronic kidney disease.
Deal Structure and Valuation
Under the agreement terms, MannKind will commence a tender offer at $5.35 per share in cash at closing, plus one non-tradable contingent value right (CVR) per share worth up to $1.00 per CVR upon achieving specific regulatory and net sales milestones. The upfront cash payment represents a 36% premium to scPharmaceuticals' 90-day volume-weighted average price, while the total consideration of up to $6.35 per share represents up to a 31% premium to the company's August 22, 2025 closing price.
The transaction represents a total equity value of approximately $303 million at closing, with the potential to reach $360 million including milestone payments. MannKind and Blackstone amended their strategic financing agreement to provide $175 million of additional funding to support the acquisition.
FUROSCIX Commercial Performance
scPharmaceuticals has demonstrated strong commercial momentum with FUROSCIX, reporting net sales of $27.8 million for the six months ended June 30, 2025, representing 96% year-over-year growth. The company has expanded its sales force in 2024 and is launching into nephrology while accelerating growth in integrated delivery networks.
The FUROSCIX ReadyFlow Autoinjector is on track for a Q3 2025 supplemental New Drug Application (sNDA) submission, potentially enabling patients to reduce treatment time from five hours to less than 10 seconds. The estimated total addressable market opportunity for FUROSCIX exceeds $10 billion in the U.S. alone.
Strategic Integration and Growth Prospects
"This acquisition expands our patient-centered brands and highlights MannKind's dedication to delivering innovative therapies for cardiometabolic and orphan lung diseases," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "With multiple anticipated product launches and indication expansions, we expect to continue to diversify our revenue streams and accelerate our double-digit growth goals over the next decade."
The combined company is expected to have a stronger revenue base with three commercial assets: Afrezza, FUROSCIX, and V-Go. These complementary commercial products, combined with Tyvaso DPI-related revenues, result in an annualized run rate of over $370 million based on Q2 2025 results.
Complementary Business Models
The acquisition leverages strategic fit between the companies' existing infrastructures. scPharmaceuticals brings deep cardiovascular expertise, while MannKind's established strength in endocrinology positions it to effectively support the recent chronic kidney disease approval for FUROSCIX. By leveraging its existing commercial infrastructure and team to engage nephrologists, MannKind aims to accelerate FUROSCIX's market opportunity in chronic kidney disease while continuing its success in chronic heart failure.
"This transaction with MannKind represents an exciting next chapter for scPharmaceuticals and the FUROSCIX brand," said John Tucker, Chief Executive Officer of scPharmaceuticals. "By combining our innovative products with MannKind's proven commercial capabilities and shared commitment to advancing patient care, we believe MannKind can accelerate access to important therapies and create meaningful value for patients, providers, and stockholders."
Pipeline and Future Catalysts
MannKind expects its commercial products to generate double-digit annual growth with several potential accelerators, including an Afrezza adult label update, India launch, and supplemental Biologics License Application submitted for pediatrics. The company is also advancing a late-stage pipeline that includes Inhaled Clofazimine (MNKD-101), currently in a phase 3 global study for nontuberculous mycobacterial lung disease, and nintedanib DPI (MNKD-201), expected to initiate a phase 2 clinical trial for idiopathic pulmonary fibrosis by year-end 2025.
Transaction Timeline
The transaction is expected to close in the fourth quarter of 2025, subject to receipt of applicable regulatory approvals and satisfaction of other customary conditions. Upon closing, MannKind will be obligated to repay and extinguish all outstanding indebtedness of scPharmaceuticals under its credit facility with Perceptive and buy-out Perceptive's rights to receive revenue payments, estimated at an aggregate amount of $81 million assuming a September 30, 2025 closing date.
